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A B S T R A C T  
  
In this study, the concentration probability distributions of 82 pharmaceutical compounds detected in the efflu- ents of 179 
European wastewater treatment plants were computed and inserted into a multimedia fate model. The comparative 
ecotoxicological impact of the direct emission of these compounds from wastewater treatment plants on freshwater ecosystems, 
based on a potentially affected fraction (PAF) of species approach, was assessed to rank compounds based on priority. As many 
pharmaceuticals are acids or bases, the multimedia fate model accounts for regressions to estimate pH-dependent fate 
parameters. An uncertainty analysis was performed by means of Monte Carlo analysis, which included the uncertainty of fate 
and ecotoxicity model input variables, as well as the spatial variability of landscape characteristics on the European continental 
scale. Several pharma- ceutical compounds were identified as being of greatest concern, including 7 analgesics/anti-
inflammatories, 3 β-blockers, 3 psychiatric drugs, and 1 each of 6 other therapeutic classes. The fate and impact modelling relied 
extensively on estimated data, given that most of these compounds have little or no experimental fate or ecotoxicity data 
available, as well as a limited reported occurrence in effluents. The contribution of estimated model input variables to the 
variance of freshwater ecotoxicity impact, as well as the lack of experimental abiotic degradation data for most compounds, helped 
in establishing priorities for further testing. Generally, the effluent concentration and the ecotoxicity effect factor were the model 
input variables with the most significant effect on the uncertainty of output results. 
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1. Introduction 
 
The presence of pharmaceuticals in the environment and 
their potential to induce adverse biological effects have been 
known for many years (Aherne and Briggs, 1989; Tabak and 
Bunch, 1970). The 
most common environmental contamination pathways are the 
emis- sion of pharmaceutical compounds from wastewater 
treatment plants (WWTPs) and the application of livestock 
manure as a top soil dressing (without previous wastewater 
treatment). Livestock manure contains veterinary drugs that 
are likely to contaminate the soil and ground- water, which, 
after rainfall incidents, can reach surface waters from 
contaminated soil by run-off. The main sources of emission for 
these environmental contamination pathways are the urinal 
and faecal excre- tion products of medically treated human 
and animals. Other less important sources of contamination 
include industrial wastewater and drugs disposed of with 
domestic waste in landfill sites, which 
  
could lead to groundwater contamination by leaching (Ternes, 
1998). The pathways of contamination after excretion and 
passage through municipal sewage systems include the 
infiltration of sewage from leak- ages in drains, the application 
of biosolids from WWTPs on agricultural areas and landscapes, 
and, due to incomplete removal, the disposal of WWTP 
effluents and raw sewage into surface waters and as reclaimed 
water into agricultural fields and landscapes by irrigation. 
Regarding these emission pathways from WWTPs, we 
distinguish between direct and indirect emissions to the 
freshwater compartment. The application of biosolids and 
effluents into agricultural soils and landscapes can also lead to 
the migration of contaminants to surface waters via run-off 
(Borgman and Chefetz, 2013; Sabourin et al., 2009); 
therefore, such emissions are defined here as indirect 
emissions to freshwater. 
Although much research has been conducted on the topic 
of direct emissions of pharmaceuticals from WWTPs, past 
studies examining the prioritisation of pharmaceuticals (e.g., 
Besse and Garric, 2008; Christen et al., 2010; Sanderson et al., 
2004) do not account for spatial variations of the 
environmental landscape, or include a comprehensive 
uncertainty and sensitivity analysis of the results when most of 
fate and impact data are estimated, nor do most of them 
account for the ionising properties of pharmaceuticals when 
most of these compounds are acids or bases. 
The aim of this study is to prioritise pharmaceutical 
compounds from WWTP direct emissions in their impact to 
freshwater ecosystems, identifying gaps of knowledge and 
relevant fate and impact issues in order to establish topics for 
further research. To provide a holistic view of the 
pharmaceuticals of greatest concern, we collected data 
concerning pharmaceutical occurrence in 179 WWTPs in 
Europe. A multimedia model representing the European 
continental scale was applied to prioritise pharmaceuticals 
according to their probabilistic impact on freshwater 
ecosystems, computed by means of Monte Carlo analysis, 
from WWTP direct emissions. Generally, experimental fate 
input variables, such as partitioning coefficients or degradation 
rates, and ecotoxicity data are scarce for most 
pharmaceuticals; therefore, estimation methods must be 
applied in an assessment. Research topics on monitoring in 
WWTP effluents, degradation in the environment or in 
ecotoxicology effects were prioritised for the compounds 
of most concern by indentifying important gaps of knowledge, 
as well as by computing the contribution of estimated model 
input variables' uncertainty and variability to the impact 
variance. Currently, a similar assessment is being performed for 
indirect emissions to the freshwater compartment. 
The multimedia model USEtox (Rosenbaum et al., 2008) was 
chosen as the basis for this comparative impact assessment 
because it results from a consensus building effort, under the 
auspices of UNEP and SETAC, amongst modellers; hence, its 
underlying principles reflect common and agreed 
recommendations from these experts. In compar- ative impact 
assessment methodologies, the conversion of emissions to 
ecotoxicological impacts comprises a fate and an effect 
analysis step (van Zelm et al., 2007). The fate factor describes 
the marginal increase in environmental concentration per unit 
of emission. The ecotoxicity effect factor (EEF) addresses the 
marginal increase in effect (toxic pressure on ecosystems) per 
unit of chemical concentration. An assess- ment factor (AF) based 
on the predicted no effect concentration (PNEC) approach is 
recommended in generic risk assessment according to the TGD 
(EC, 2003); however, a potentially affected fraction (PAF) of species 
approach based on the average toxicity was considered in the 
present study as a basis for the EEF calculation, as adopted in 
the USEtox model. Both approaches have advantages and 
drawbacks (Larsen and Hauschild, 2007a,b); however, a PAF-
based approach has two main ad- vantages that better serve the 
purposes of this study: 1) a PNEC ap- proach targets the 
protection of the most sensitive species; therefore, the risk of 
bias is high when scarce ecotoxicity data are available, which 
is the case for pharmaceuticals; and 2) the assessment of the 
mean impact (AMI) on ecosystem method, a PAF-based 
approach, allows the quantification of uncertainty, giving an 
indication of  the 
 reliability of the results. The AMI method is based on the 
hazardous con- centration (HC) at which the effect 
concentration (with an endpoint of, for example, mortality) 
affecting 50% of tested individuals (EC50) is exceeded for 
50% of the included species; this is also called HC50EC50 
(Payet, 2004, 2005; Payet and Jolliet, 2005). Two statistical 
estimators can be used to estimate the toxicity of a substance 
to biological species and the associated confidence interval: 
a non-parametric estimator using the median as the 
HC50EC50 combined with bootstrap statistics to estimate its 
uncertainty (Payet and Jolliet, 2005) or a parametric 
estimator based on the assumption of a lognormal 
distribution of data using the geometric mean as HC50EC50 
and Student's t-statistics for its confidence interval (Payet, 
2004, 2005). 
 
2. Methodology 
 
2.1. Emission data 
 
A survey of the occurrence of pharmaceuticals in the 
effluents of European WWTPs was performed to compute 
concentration probability distributions. The survey is based 
on a recent review conducted by Verlicchi et al. (2012) on 
the global occurrence of pharmaceuticals in urban 
wastewater. For this Europe-focused study, 54 peer-
reviewed publications were identified from the cited review 
covering 179 WWTPs located in Austria, Denmark, Finland, 
France, Germany, Greece, Italy, Spain, Sweden, Switzerland, 
and the UK, with capacities ranging from 6000 to 2500000 
population equivalents. Effluent con- centration data 
included 82 drugs pertaining to 15 different classes: 19 
analgesics/anti-inflammatories (including 1 metabolite), 15 
antibi- 
otics, 12 β-blockers, 7 psychiatric drugs, 7 lipid regulators 
(including 2 
metabolites), 4 hormones, 4 β-agonists, 3 receptor 
antagonists, 3 anti- 
neoplastics, 2 antihypertensives, 2 diuretics, 1 proton-pump 
inhibitor, 1 antiseptic, 1 contrast agent, and 1 antifungal 
(Supplementary data, Table S3). The quality of effluent 
concentration data reported in the lit- erature has been 
confirmed according to the EC Technical Guidance 
Document (TGD) on Risk Assessment (EC, 2003). Therefore, 
the refer- ences included in the survey feature a description 
of the analytical methodology and the quality assurance 
programme used for sampling, analysis and elaboration. 
Considering only WWTPs with data available on population 
served (number of the inhabitants in the catchment), the 
effluent concentration in each WWTP was weighted by the 
popula- tion served and the geometric mean and the 
geometric standard devia- tion of the effluent concentration, 
in mg/l, in European WWTPs were computed. Aggregated 
data on a compound concentration in several WWTPs 
effluents were weighted using the aggregated data on popula- 
tion served. The probability distribution, assuming a lognormal 
distribu- tion, of the effluent concentration of each compound 
was used as input into a multimedia fate and transport model, 
assuming steady-state con- centrations, to assess the 
comparative impact to freshwater ecosystems. 
 
2.2. Fate modelling 
 
Fate factors describing the marginal increase in 
environmental concentration of pharmaceuticals per unit of 
emission were computed by a model based on the multimedia 
model USEtox (Rosenbaum et al., 2008) and described in detail 
in Morais et al. (2013a,b). The difference between models 
refers to the inclusion of regressions to estimate pH- 
dependent fate parameters if no suitable experimental values 
are avail- able, such as the solid-water partitioning coefficient 
normalised by the organic carbon, KOC (Franco and Trapp, 
2008) and the bioconcentration factor in fish, BCFfish (Fu et al., 
2009). Over 60% of pharmaceuticals are acids or bases that are 
fully or partially dissociated at environmental pH (Avdeef, 
2003); hence, conventional non-polar regressions cannot be 
applied without considering the ionisation of pharmaceuticals 
(Escher et al., 2011; Tarazona et al., 2010). For the 
environmental compartments evaluated, the landscape 
characteristics of the USEtox European continental scale were 
applied. The fate model   accounts 
  
 
 
Fig. 1. Three-compartment system for the dissipation of pharmaceuticals from direct emissions to 
freshwater of WWTP effluents. 
 
for inter-media transport processes, intramedia partitioning 
and degradation in the environment (Fig. 1) and is further 
described in Supplementary data, sections S1 and S2. 
Abiotic degradation mechanisms in the freshwater 
compartment are important elimination processes for 
pharmaceuticals (Andreozzi et al., 2003; Doll and Frimmel, 
2003). However, the USEtox model does not address 
estimation procedures for these mechanisms; therefore, to esti- 
mate direct and indirect photodegradation rates, a number of 
models and assumptions were applied and are described in 
detail in Morais et al. (2013a,b). A short description is 
provided in Supplementary data, section S2. 
 
2.3. Ecotoxicity effect factor 
 
The EEF indicator, i.e., 0.5/HC50EC50, in PAF∙m3 kg−1, 
focuses on the trophic structure by including the EC50 values 
of at least 3 trophic levels: primary producers (algae), 
primary consumers (crustaceans), 
and secondary consumers (fish) (Supplementary data, Table 
S5). The low environmental concentrations but constant 
introduction to the en- vironment indicate that pharmaceuticals 
are more likely to have chronic rather than acute toxic effects 
on aquatic biota (Carlsson et al., 2006; Fent et al., 2006; Quinn 
et al., 2008); hence, chronic EC50 values are pre- ferred as well 
as, due to the comparative context of the assessment, 
standard tests/test conditions and standard test organisms. 
However, the ecotoxicological data on pharmaceuticals 
remain scarce, and there are not enough chronic 
experimental ecotoxicity data available to perform an 
assessment (Escher et al., 2011). An acute–chronic ratio of 2 
was applied to extrapolate chronic HC50EC50 values from 
acute HC50EC50 values, as recommended by Larsen and 
Hauschild (2007b), and was applied in the USEtox model 
(Huijbregts et al., 2010). However, the best estimate AFs for this 
extrapolation have not yet been devel- oped, and research is 
needed in this area (Larsen and Hauschild, 2007b), 
particularly in the context of micropollutants. Even acute 
ecotoxicity data are only available for a very limited set of 
pharmaceuti- cals (Escher et al., 2011); therefore, EC50 values 
are completed by extrapolation from the lowest observed 
effect concentration (LOEC) or no observed effect 
concentration (NOEC) values, according to the best-estimate 
AFs from Payet (2004). To determine missing experimen- tal data, 
quantitative–structure activity relationship (QSAR) data were 
included using the software programme ECOSAR v1.00 (Nabholz 
and Mayo-Bean, 2009). For estimated data, a conservative 
approach was followed by considering the chemical class with 
the highest potency (i.e.,  the lowest concentration  predicted 
to  cause the toxic   effect), 
 except in the case of the neutral organics class if a 
compound is completely dissociated at environmentally 
relevant pH values. 
The baseline toxicity, or narcosis, is the addressed toxic 
mode of action (TMoA) in most generic risk assessment or 
impact assessment methodologies. Previous studies have 
shown that most pharmaceuticals produce their environmental 
adverse effect via narcosis (Sanderson and Thomsen, 2007). 
However, some pharmaceuticals, which are designed to be 
bioactive (with the exception of contrast agents), also 
exhibit a therapeutic effect in non-target aquatic life, such as 
the estrogenic effects caused by hormones in fish (Santos et 
al., 2010), or they act via a specific TMoA, such as the 
inhibition of photosynthesis caused by β-blockers in algae 
(Escher et al., 2006). As a change in sex ratio appar- ently 
relates directly to the reproduction of a fish population, 
this endpoint is considered more relevant than vitellogenin 
in an impact assessment context (Larsen et al., 2010). 
Hence, the endpoints used for the average toxicity 
calculation include the inhibition of growth and 
photosynthesis for algae, mortality or immobility (Daphnia) 
for invertebrates, and mortality or change in sex ratio for fish. 
 
2.4. Uncertainty and sensitivity analysis 
 
The propagation of the uncertainty and variability of 
model input variables in the output results was quantified 
by Monte Carlo analysis. The model output is the ecotoxicity 
impact on freshwater, in 
PAF∙m3 d. The parameters included in the analysis are described 
in the Supplementary  data,  Table  S6. The analysis  includes  
the following 
factors: 
 
(1) The variability of effluent concentrations, direct 
photolysis rates (kphoto, fw) and continental-scale 
environmental parameters (freshwater pH, rainfall, 
freshwater concentration of suspended matter, 
dissolved organic carbon, and •OH). For each 
pharmaceu- tical, the maximum and minimum of the 
uniformly distributed photodegradation rate 
parameter were obtained considering results for the 
winter and summer seasons, the latitudes of 40 and 
60, and experimental quantum yields (see 
Supplementary data, section S2) 
(2) The uncertainty of the EEF. Uncertainty distributions of 
HC50EC50 values were estimated according to the 
parametric estimator, as recommended by Payet 
(2004). Moreover, the parametric esti- mator is based 
on the geometric mean, which is the most robust 
average estimator for HC50EC50 (Larsen and Hauschild, 
2007b). However, the uncertainty of extrapolating 
average chronic 
  
toxicity, i.e., chronic HC50EC50, from average acute 
toxicity was not addressed in the present study, nor was 
the uncertainty of extrapolating and estimating individual 
endpoints. 
(3) The uncertainties associated with the regression 
equations adopted  in  the  model  to  estimate  
partition coefficients (KOC and KOW), bioconcentration 
factors in fish (BCFfish) and bio- transformation rates 
(kbio, fw). The procedure to compute the un- certainty 
descriptors of regressions equations is described in 
detail in Morais et al. (2013a,b). In short, the training and 
valida- tion sets used to derive the regression methods 
applied in the present study (Franco and Trapp, 2008; Fu 
et al., 2009; USEPA, 2008a, 2009) were used to derive 
mean residual errors and their uniformal distributions 
and were fit into the regressions. 
(4) The uncertainty associated with experimental parameter 
values (partition coefficients, biotransformation half-
lives, and kOH). The geometric mean and the geometric 
standard deviation of experimental values were set as 
uncertainty descriptors, assum- ing a lognormal 
distribution. 
 
The identification of relevant parameters to the impact 
variance, performed by a sensitivity analysis, enables setting 
research priorities. The contribution to the variance provides an 
approximation of the per- centage of the variance or 
uncertainty of an output result caused by the variability or 
uncertainty of a given model parameter. The contribution was 
calculated by squaring the correlation coefficients between 
model input variables and impact results, for a given number 
of trials, and normalising them to 100%. 
 
3. Results and discussion 
 
Fig. 2 shows the comparative ecotoxicological impact of 
pharmaceu- ticals emitted directly from WWTP effluents to the 
freshwater compart- ment. In order to rank compounds for 
further discussion the contribution of each pharmaceutical's 
uncertainty to the variance of total ecotoxicity 
was calculated. A general condition for impact assessment 
methodolo- gies is that the impact indicator be additive 
(Larsen and Hauschild, 2007b); however antagonistic–
synergistic interactions in mixtures of pharmaceuticals are not 
accounted for in such approaches. The total ecotoxicity impact 
is 6.51 × 10−2 PAF m3 d per m3 of effluent (95% con- fidence 
interval = 2.84 × 10−2–6.61 × 10−1). The contribution of each 
pharmaceutical's uncertainty to the variance of total ecotoxicity 
can be computed; these results are shown in Fig. 3. It is assumed 
that the phar- maceuticals of most concern are those totalling a 
90% contribution to the total impact variance. For the 
pharmaceuticals of most concern, the con- tribution of model 
input variables to the variance of the results of Fig. 2 is shown in 
Fig. 4. Generally, for the substances of most concern, the HC50 
parameter is the most relevant one for the statistical spread of 
impact re- sults shown in Fig. 2. For most substances, the 
parametric quantification of HC50 uncertainty is based on only 3 
data values, which typically pro- duces wide confidence limits 
(Larsen and Hauschild, 2007a), making the statistical 
differentiation between substances ambiguous. Compounds of 
most concern are further discussed by dividing the most 
relevant therapeutical classes into sections. 
 
3.1. Antineoplastics 
 
The antineoplastic tamoxifen displays the highest median 
ecotoxicity impact (Fig. 2). The uncertainty of the HC50 parameter 
contributes 93.8% of the variance of the tamoxifen impact results 
(Fig. 4). Only 2 experimen- tal acute EC50 values, covering 1 
trophic level, were obtained in the present study 
(Supplementary data, Table S5). The ecotoxicological datum 
on algae was estimated by ECOSAR. The quantification of this 
QSAR method's uncertainty is not considered in the present 
study, as stated in Section 2.4; therefore, its influence on impact 
results is unclear. In addition, the EC50 value for crustaceans 
was extrapolated from the NOEC. The inherent uncertainty of 
extrapolating ecotoxicological endpoints is also not 
considered in the present study. Overall, a more 
comprehensive ecotoxicological study is needed. Moreover, 
the 
 
 
  
 
Fig. 2. Probability distribution median and 95% confidence interval of ecotoxicity impact, in PAF m3 d, of 
pharmaceuticals on freshwater per m3 of WWTP effluent. 
  
 
 
Fig. 3. Contribution to variance of total freshwater ecotoxicity impact. 
 
 
calculated impact of tamoxifen is based on very limited data on 
measure- ments in WWTP effluents (e.g., Roberts and Thomas, 
2006) According to the outcome of the present study, tamoxifen 
should be subject to moni- toring in WWTP effluents for more 
conclusive results. The neutral form of tamoxifen, with an 
estimated log KOW of 6.30 (USEPA, 2008b), is highly hydrophobic. 
Moreover, tamoxifen is predominantly found in the basic form 
at pH 7 (pKa = 8.52); therefore, electrostatic interactions 
may play a significant role in its partitioning into negatively 
charged sorption sites of particles and, consequently, in its 
removal from WWTPs. The 
 
environmental occurrence of tamoxifen is, however, common 
(e.g., Hilton and Thomas, 2003; Roberts and Thomas, 2006; 
López-Serna et al., 2012). Another issue of concern, and a 
subject for further study, is the depletion of tamoxifen, which 
may be underestimated in the aquatic environment because no 
data on indirect photolysis are available in the literature, such as 
bimolecular rate constants for the reaction between the 
compounds and chemical transients. This compound, which 
has double bonds and aromatic rings, may react with chemical 
transients generated by natural water constituents under 
sunlight, especially with 
 
 
  
 
Fig. 4. Contribution of model input variables to impact variance of pharmaceuticals of most 
concern. 
  
the extremely reactive hydroxyl radical that can abstract 
hydrogen from saturated organics, add to double bonds or 
add to aromatic rings. In contrast, the chronic ecotoxicity of 
tamoxifen derivatives produced by direct photolysis revealed 
no significant differences in comparison to the parental 
compound (DellaGreca et al., 2007); therefore, the overall 
impact of tamoxifen may be underestimated, given that 
photoproducts were not included in the present study. 
 
3.2. Analgesics/anti-inflammatories 
 
Mefenamic acid is a widely used non-steroidal anti-
inflammatory compound and is commonly found in WWTP 
effluents (e.g., Barron et al., 2009; Radjenovic et al., 2009; 
Rosal et al., 2010; Tauxe-Wuersch et al., 2005). Literature 
data on mefenamic acid concentrations in WWTP effluents 
vary by 3 orders of magnitude, from 0.005 (Kasprzyk-
Hordern et al., 2009) to 3.0 μg/l (Tauxe-Wuersch et al., 
2005). The variability of the effluent concentration contributes 
97.7% of the variance of the impact of mefenamic acid (Fig. 4). 
However, the calculated effect of this anti-inflammatory may 
be overestimated, given that Werner et al. (2005) suggested 
that photosensitisation by ex- cited triplet-state DOM may 
contribute to the environmental degrada- tion of mefenamic 
acid. The influence of this degradation mechanism on the 
calculated effect remains unknown in the present study. 
The calculated impact of aminopyrine is based on estimated 
ecotox- icological data. Even excluding the uncertainty of 
ecotoxicity data estimation, the HC50 parameter has a 
contribution of 97.4% to the vari- ance of the impact of 
aminopyrine. Moreover, this compound is not commonly 
detected in WWTP effluents (e.g., Ternes, 1998; Andreozzi et 
al., 2003). Poor sorption to particles in WWTPs may be 
expected, given that the predominant neutral form of this basic 
compound at pH 7 (pKa = 5.0) has an estimated log KOW of 
0.6 (USEPA, 2008b). There- fore, depending on the role of its 
biotransformation in WWTPs, a very low influent 
concentration or non-existent discharge may have been 
observed in WWTPs; nevertheless, no data on influent 
concentrations were reported in the literature. In fact, the 
human clinical use of amino- pyrine is widely banned due to 
the risk of agranulocytosis and due to its potential to produce 
carcinogenic nitrosamines (U.N., 2003); hence, its presence in 
WWTP discharges may be caused by low levels of appli- cation 
in veterinary medicine or by industrial release (Ternes, 1998). 
No abiotic degradation data are available; however, 
aminopyrine is ex- pected to be susceptible to indirect 
photolysis. In addition, it contains chromophores that absorb 
at wavelengths N 290 nm and may therefore also be 
susceptible to direct photolysis; hence, the residence time of 
aminopyrine in the aquatic environment may be overestimated. 
The concentration reported in the literature on the 
occurrence of the opiate codeine in WWTP effluents varies by 
3 orders of magnitude (Gómez et al., 2007; Wick et al., 
2009), from 0.022 to 15.59 μg/l. This variability of the effluent 
concentration contributes 66.6% of the variance of impact 
results. The HC50 parameter contributes 32.8%; furthermore, 
estimated data were applied and, as stated above, the 
quantification of uncertainty in endpoints estimation was not 
consid- ered in the present study; therefore, the influence of 
using estimated data on impact variance is unclear. Codeine is 
expected to be susceptible to indirect photolysis and contains 
chromophores that absorb at wavelengths N 290 nm; 
therefore, it may also be susceptible to direct photolysis. 
The concentration of tramadol in WWTP effluents reported 
in the literature varies by 3 orders of magnitude, from 0.02 to 
97.62 μg/l (Kasprzyk-Hordern et al., 2009; Wick et al., 2009). The 
effluent concen- tration of tramadol contributes 75.3% to the 
impact variance. The HC50 parameter represents 24.1% of the 
tramadol impact result variance; fur- thermore, for experimental 
EC50 values of 2 trophic levels, crustaceans and fish, the species 
were not specified in the literature. In terms of environmental 
occurrence, tramadol was detected in 2 rivers in South Wales, 
UK at a maximum concentration of 5970 ng/l (Kasprzyk- 
Hordern et al., 2009). 
 3.3. β-Blockers 
 
The HC50 parameter contributes between 70 and 86% to 
the impact results for variance of the β-blockers betaxolol, 
oxprenolol, and propanolol. Moreover, oxprenolol ecotoxicity 
data have been estimated for all trophic levels, and in the case 
of betaxolol, only 1 acute EC50 value is experimental. 
Propanolol is commonly measured in WWTP effluents (e.g., 
Alder et al., 2010; Maurer et al., 2007; Wick et al., 2009); 
however, limited data are available on the occurrence of 
oxprenolol and betaxolol in WWTP effluents (Ternes, 1998; 
Andreozzi et al., 2003). According to the molecular structures 
of β-blockers, indirect photolysis may play a role in their 
persistence in the aquatic environment; however, except for 
propanolol, no experimental data on photosensitisation 
were found in the literature; therefore, its residence time in 
the aquatic envi- ronment may be overestimated. In fact, in 
terms of environmental occurrence, no literature data on 
oxprenolol were found; however, betaxolol was not 
detected in 29 rivers in Germany, even when it was present 
in WWTP effluents (Ternes, 1998), nor was it detected in the 
Ebro River in Spain (López-Serna et al., 2012). 
 
3.4. Psychiatric drugs 
 
In addition to the high contribution of the HC50 
parameter to the variance impact of the tricyclic 
antidepressant amitriptyline (95.9%), the experimental 
ecotoxicological data were limited to crustaceans, with 
chronic EC50 values for 4 species. In the case of other trophic 
levels, ECOSAR values were applied. Both the high sorption 
potential of the neutral form, with an estimated log KOW of 
4.95 (USEPA, 2008b), and the predominance of the basic 
form at pH 7 (pKa = 9.4) indicate signif- icant removal in 
WWTPs. Nevertheless, the literature data (both on 
measurements of amitriptyline in WWTP effluents and on 
the fate of amitriptyline in WWTPs) are too limited for 
conclusive results. In addition, according to its molecular 
structure, amitriptyline may be sus- ceptible to indirect 
photolysis; hence, its residence time in the aquatic 
environment may be overestimated in the present study. 
The impact of diazepam is comparatively significant for the 
higher concentrations in WWTP effluents that have been 
reported in the liter- ature (Supplementary data, Table S3). This 
parameter has a contribution of 92.5% to the impact variance. 
The concentration ranges 3 orders of magnitude, from 0.04 
to 19.3 μg/l (Suárez et al., 2005; Ternes, 1998); however, 
measurements of this compound in WWTP effluents are 
very scarce in the literature. 
The HC50 parameter contributes 43.3% to impact variance 
of the se- rotonin reuptake inhibitor fluoxetine. Three acute 
experimental HC50s covering 3 trophic levels were applied. An 
acute LC50 value was applied for fish; however, for fluoxetine, 
other TMoAs such as endocrine disrup- tion may be relevant, 
given that Mennigen et al. (2008) suggested that fluoxetine 
may have the potential to affect sex hormones and modulate 
genes involved in the reproductive function of fish. The effluent 
concen- tration has a contribution of 39.4% to the impact 
variance. Although direct photolysis could potentially limit 
the persistence of fluoxetine in surface waters, Lam et al. 
(2004) suggested that its degradation by indirect photolysis 
would be the limiting degradation mechanism. 
 
3.5. Other therapeutical classes 
 
The statistical spread of the antifungal clotrimazole's impact 
is also mainly due to the HC50 parameter, with a 95% 
contribution to the variance. According to its molecular 
structure, clotrimazole is expected to be susceptible to indirect 
photolysis; therefore, its residence time in the aquatic 
environment may be overestimated. The neutral form of 
clotrimazole, which predominates at pH 7 (pKa = 5.22), is 
highly hy- drophobic, with an estimated log KOW of 6.26 
(USEPA, 2008b); there- fore, significant partitioning to 
particles in WWTPs may be observed. There are limited data 
on the occurrence of this topical product in WWTP effluents 
at detectable concentrations (OSPAR, 2005); however, 
  
clotrimazole is a widely used over-the-counter antifungal agent. 
More- over, in terms of environmental occurrence, 
clotrimazole was the most frequently detected of 14 
pharmaceuticals analysed in UK estuaries, with median 
concentration of 7 ng/l (Hilton and Thomas, 2003); in ad- 
dition, it was detected with a median concentration of 21 
ng/l in the River Tyne, UK (Roberts and Thomas, 2006); 
nevertheless, it was not detected in the Elbe and Saale Rivers in 
Germany at any of the measured points (OSPAR, 2005). 
The HC50 parameter contributes 59% to the impact variance 
of the antihypertensive receptor diltiazem. This parameter is of 
even greater concern, given that only 1 experimental EC50 
value was found in the literature (Supplementary data, Table 
S5). 
No abiotic degradation data are available. However, 
diltiazem is expected to be susceptible to indirect photolysis 
since it has double bonds and aromatic rings, and because it 
has chromophores that absorb at wavelengths N 290 nm, it has 
the potential to be degraded by direct photolysis; therefore, 
the depletion of diltiazem in the aquatic environ- ment may be 
underestimated. 
The HC50 parameter contributes 95% to the impact 
variance of the proton-pump inhibitor omeprazole. Moreover, 
only 1 experimental EC50 value was found in the literature 
(Supplementary data, Table S5). Very limited data on 
measurements of omeprazole in WWTP effluents are available 
in the literature (Rosal et al., 2010); nevertheless, it is one of 
the most widely prescribed pharmaceuticals. Omeprazole is 
expected to undergo hydrolysis in the environment due to the 
presence of functional groups that hydrolyse under 
environmental conditions, and it may also be susceptible to 
direct and indirect photolysis (DellaGreca et al., 2006); 
however, no experimental data were found in the literature. 
In addition to the high contribution of HC50 to the variance 
of the macrolide antibiotic azithromycin's impact result 
(52.2%) all EC50 values were estimated. The effluent 
concentration contributes 46.7% to the impact variance. The 
photodegradation of azithromycin was shown to be 
enhanced in the presence of nitrates and humic acids (Tong 
et al., 2011), which indicates the role of indirect photolysis in 
the  persistence  of  this  compound  in  the  environment. 
However, 
indirect photodegradation was not included in the present 
study for this compound; therefore, the impact of 
azithromycin is most likely overestimated. 
Concentrations of the hormone 17β-estradiol in WWTP 
effluents reported in the literature vary by 2 orders of 
magnitude, from 0.0007 to 0.0180 μg/l (Baronti et al., 2000; 
Clara et al., 2004). The variability of effluent concentration 
represents 63.6% of the impact variance. The HC50 parameter 
contributes 29.2% to the variance. Experimental acute EC50 
values for 6 species were applied; however, the EC50 value 
for algae was estimated. 
The diuretic bendroflumethiazide, the anti-inflammatories 
5- aminosalicylic acid and ketorolac, and the lipid regulator 
clofibrate are discussed in the Supplementary data (Section 5). 
 
3.6. Additional considerations 
 
Table 1 summarises future research topics for the 
pharmaceuticals of greatest concern. These topics can be 
related to 3 issues: a) the fate of pharmaceuticals in WWTPs, 
b) substance-specific modelling parame- ters, and c) lack of 
spatial and time resolution models. The first topic includes 
compounds with very limited data on measurements or detec- 
tion in WWTP effluents, such as tamoxifen or amitriptyline. 
These sub- stances should be subject to further monitoring in 
WWTPs, depending on geographical usage patterns, for more 
conclusive results. This catego- ry should also include 
compounds whose impact result would be most sensitive to 
variations of the emission concentration. Ideally, a compar- 
atively well characterised drug from an impact perspective 
would account for low variance of output results due to 
environmental fate and transport modelling parameters, either 
estimated or experimental, and due to EEF characterisation. 
The uncertainty of its impact result, from a modelling 
perspective, would be related mainly to the variability of the 
concentration in WWTP effluents, depending on geographical 
and seasonal usage patterns, treatment technologies, and 
operation condi- tions. The focus of research for these 
compounds should be detailed eco- logical risk assessments 
possibly leading to research and development on the 
operation and design of WWTPs to improve the reduction  of 
 
 
Table 1 
Research topics for pharmaceuticals of most concern. Three arrows denote a research topic of higher concern, two arrows 
denote a research topic of moderate concern, and one arrow denotes a research topic lower concern. 
 
 Effluent 
characterisationa 
Ecotoxicological effect 
characterisationb 
Parameter 
incompleteness 
  
  Abi tic degradation 
mechanismsc 
Derivative 
toxicityd 17β-Estradiol ↓↓ ↓  ↓↓  
5-Aminosalicylic 
acid 
↓↓↓ ↓↓↓ ↓↓ ↓↓  
Aminopyrine ↓↓↓ ↓↓↓ ↓↓ ↓↓  
Amitriptyline ↓↓↓ ↓↓↓ ↓ ↓↓  
 
Azithromycin 
Bendroflumet
hiazide 
↓↓↓ 
↓↓↓ 
↓↓↓ 
↓↓↓ 
(↓↓) 
↓↓ 
↓↓ 
↓↓ 
 
Betaxolol ↓↓ ↓↓↓ ↓ ↓↓  
Clotrimazole ↓↓↓ ↓↓ ↓ ↓↓  
Codeine ↓↓ ↓↓↓ ↓↓ ↓↓  
Diazepam ↓↓ ↓  ↓↓  
Diltiazem ↓↓↓ ↓↓↓ ↓↓ ↓↓  
Fluoxetine ↓↓ ↓↓  ↓↓  
Ketorolac ↓↓↓ ↓↓↓ ↓↓ ↓↓  
Mefenamic acid ↓↓ ↓ (↓↓) ↓↓  
Omeprazole ↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓  
Oxprenolol ↓↓↓ ↓↓↓ ↓ ↓↓  
Propranolol • ↓  ↓↓  
Tamoxifen ↓↓ ↓↓↓ ↓ ↓ (↓↓)  
Tramadol ↓↓ ↓↓  ↓↓  
a    •: more than 10 peer-reviewed publications; ↓: between 5 and 10 peer-reviewed publications; ↓↓: between 2 and 5 
peer-reviewed publications; ↓↓↓: only one peer-reviewed publication. 
b    ↓: more than 3 acute EC50s covering 3 trophic levels; ↓↓: 3 acute EC50s covering 3 trophic levels; ↓↓↓: at least 1 
estimated or extrapolated EC50. 
c   Number of possible abiotic degradation mechanisms not included in the assessment (hydrolysis, direct and indirect 
photolysis); (↓↓) denotes a specific degradation pathway with some evidence of occurrence in the literature but with no 
data available. 
d    Number of possible degradation mechanisms generating derivatives (hydrolysis, photolysis and biodegradation); (↓↓) 
denotes a specific degradation pathway with evidence of 
derivatives toxicity in the literature. 
  
the compounds' effluent concentrations. However, the 
compounds most sensitive to the emission concentration, 
such as diazepam or mefenamic acid, have other research 
priorities either because of limited data on their occurrence or 
incomplete modelling parameters. 
The second issue includes drugs whose impact results are 
mostly sensitive to the uncertainty of substance-specific 
modelling parameters, such as degradation rates or 
partitioning coefficients, or to EEF characterisation. It also 
includes drugs whose impact result may be affected by 
modelling incompleteness, either from the lack of abiotic 
degradation data (such as for omeprazole or azithromycin) or 
from the exclusion of degradation products (such as for 
tamoxifen). These compounds should be subjected to further 
experimental research according to the most sensitive 
parameters because of a lack of precise knowledge regarding 
those parameters. The third issue, the lack of spa- tial and time 
resolution models, addresses the variability of landscape 
parameters, such as freshwater pH or [•OH], and the seasonal 
variation of direct photolysis rates. However, for the 
compounds of greatest con- cern, only the spatial variability is 
somewhat significant, and only in the case of [•OH]. The large 
scale applied in the present study displays a great variety of 
landscape characteristics; nevertheless, the uncertainty 
regarding the HC50 parameter and the variability of the 
effluent concentration predominate in terms of the 
contribution of variance to the output results. 
 
 
3.7. Model limitations 
 
It should be noted that other sources of uncertainty not 
included in the Monte Carlo analysis may be important. Some 
have already been discussed above, such as the uncertainty of 
ecotoxicological data esti- mation, the extrapolation of 
endpoints, the lack of abiotic degradation data for several 
compounds, and the exclusion of abiotic and biotic 
derivatives of parent compounds. This last source of 
uncertainty may be relevant in the case of tamoxifen, as 
already mentioned; however, substances that do not appear 
in the ranking of compounds of most concern may have their 
comparative impact substantially increased by the inclusion of 
their derivative impact. For example, some researchers have 
suggested that the phototransformation products of 
triclosan, diclofenac or hydrochlorothiazide have a higher 
toxicity potential than their parent compounds (Han et al., 2000; 
Schmitt-Jansen et al., 2007). Nevertheless, the inclusion of 
phototransformation product impact is possible, if the 
chemical structures are identified, by applying the method 
proposed by van Zelm et al. (2010). 
In addition, the uncertainty of the influence of pH on 
direct and indirect photolysis rates, the uncertainty of the 
application of a linear dose–response curve for the calculation 
of EEFs, and the lack of spatial variation of background impacts 
in the AMI method remain unclear. For example, for 
uncertainty of the influence of pH on the abiotic 
degradation, the literature data on the direct 
phototransformation of triclosan (pKa = 8.1) applied in the 
present study are based on its anionic form (Tixier et al., 2002), 
which is the dominant photochemical degradation pathway. 
Therefore, by disregarding the influence of pH on the direct 
photolysis rate,  the  residence  time  of  triclosan in the 
freshwater environment may be underestimated for lower pH 
values. 
A first screening approach to deal with the uncertainty of 
speciation of an organic compound could be based on a 
uniformal distribution using the lowest and highest degradation 
rates amongst all the species involved in the speciation as the 
minimum and maximum. Therefore, quantum yields and 
experimental molar absorption coefficients in func- tion of the 
UV/VIS wavelength range of all the species involved must be 
experimentally obtained and applied to models that compute 
direct photolysis rates and half-lives of pollutants in the aquatic 
environment. A similar approach can be applied for indirect 
photolysis by obtaining experimental rate constants between 
chemical transients and all the chemical species involved in the 
speciation. 
 4. Conclusions 
 
Despite the high uncertainties of the pharmaceutical impact 
results, which range up to 12 orders of magnitude, and the 
model's limitations and parameter incompleteness, the 
outcome of the present study allows priorities to be set for 
further experimental testing. Several pharmaceu- tical 
compounds were identified as being of greatest concern, 
including 7 analgesics/anti-inflammatories, 3 β-blockers, 3 
psychiatric drugs, and 1 each of 6 other therapeutic classes. 
Notably, some pharmaceuticals identified as of greatest 
concern, such as tamoxifen, clotrimazole and oxprenolol, have 
rarely been inves- tigated previously with regard to their 
ecotoxicity, their occurrence in WWTPs, or their degradation 
in the environment. Theoretically, the relevant 
pharmaceuticals may be susceptible to abiotic degradation. 
However, in general, no experimental data are available; hence, 
the per- sistence of these pharmaceuticals in the freshwater 
compartment is es- timated to be comparatively higher 
than that of well-researched pharmaceuticals that were not 
included on the ranking of priority com- pounds, such as 
triclosan, diclofenac or ibuprofen. 
Ecotoxicity data remain to be the most critical issue 
affecting impact or risk assessments of pharmaceuticals. The 
present assessment is based on only 3 data values for most of 
priority pharmaceuticals (only approximately 4% of these 
compounds have more than 3 EC50 values) that produced 
wide confidence limits. Moreover, approximately 58% of the 
pharmaceuticals of priority have at least 1 estimated or 
extrapo- lated EC50. 
In short, this study identified several pharmaceuticals 
both for further WWTP monitoring and for testing their 
ecotoxicity and their persistence in the environment. 
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